Impact of microsatellite status in early-onset colonic cancer.
Détails
ID Serval
serval:BIB_82B744948C64
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Impact of microsatellite status in early-onset colonic cancer.
Périodique
The British journal of surgery
Collaborateur⸱rice⸱s
REACCT Collaborative
Contributeur⸱rice⸱s
Adamina AAM, Aigner F., d'Allens L., Allmer C., Álvarez A., Anula R., Andric M., Bach SAS, Bala M., Barussaud M., Bausys A., Beggs A., Bellolio F., Bennett M.R., Berdinskikh A., Bevan V., Biondo S., Bislenghi G., Bludau M., Brouwer N., Brown C., Bruns C., Buchanan D.D., Buchwald P., Burger JWA, Burlov N., Campanelli M., Capdepont M., Carvello M., Chew H.H., Christoforidis D., Clark D., Climent M., Collinson R., Cologne K.G., Contreras T., Croner R., Daniels I.R., Dapri G., Davies J., Delrio P., Denost Q., Deutsch M., Dias A., D'Hoore A., Drozdov E., Duek D., Dunlop M., Dziki A., Edmundson A., Efetov S., El-Hussuna A., Elliot B., Emile S., Espin E., Evans M., Faes S., Faiz O., Figueiredo N., Fleming F., Foppa C., Fowler G., Frasson M., Forgan T., Frizelle F., Gadaev S., Gellona J., Glyn T., Goran B., Greenwood E., Guren M.G., Guillon S., Gutlic I., Hahnloser D., Hampel H., Hanly A., Hasegawa H., Iversen L.H., Hill A., Hill J., Hoch J., Hompes R., Hurtado L., Iaquinandi F., Imbrasaite U., Islam R., Jafari M.D., Salido A.J., Jiménez-Toscano M., Kanemitsu Y., Karachun A., Karimuddin A.A., Keller D.S., Kelly J., Kennelly R., Khrykov G., Kocian P., Koh C., Kok N., Knight K.A., Knol J., Kontovounisios C., Korner H., Krivokapic Z., Kronberger I., Kroon H.M., Kryzauskas M., Kural S., Kusters M., Lakkis Z., Lankov T., Larson D., Lázár G., Lee K.Y., Lee S.H., Lefèvre J.H., Lepisto A., Lieu C., Loi L., Lynch C., Maillou-Martinaud H., Maroli A., Martin S., Martling A., Matzel K.E., Mayol J., McDermott F., Meurette G., Millan M., Mitteregger M., Moiseenko A., Monson J.R., Morarasu S., Moritani K., Möslein G., Munini M., Nahas C., Nahas S., Negoi I., Novikova A., Ocares M., Okabayashi K., Olkina A., Oñate-Ocaña L., Otero J., Ozen C., Pace U., Julião GPS, Panaiotti L., Panis Y., Papamichael D., Patel S., Uriburu JCP, Peng S.L., Pera M., Perez R.O., Petrov A., Pfeffer F., Phang T.P., Poskus T., Pringle H., Proud D., Raguz I., Rama N., Rasheed S., Raval M.J., Rega D., Reissfelder C., Meneses JCR, Ris F., Riss S., Rodriguez-Zentner H., Roxburgh C.S., Saklani A., Sammour T., Saraste D., Schneider M., Seishima R., Sekulic A., Seppala T., Sheahan K., Shlomina A., Sigismondo G., Singnomklao T., Siragusa L., Smart N., Solis-Peña A., Spinelli A., Staiger R.D., Stamos M.J., Steele S., Tan K.K., Tanis P.J., Tekkis P., Teklay B., Tengku S., Tsarkov P., Turina M., Ulrich A., Vailati B.B., van Harten M., Verhoef C., Warrier S., Wexner S., de Wilt H., Weinberg B.A., Wells C., Wolthuis A., Xynos E., You N., Zakharenko A., Zeballos J., Zhou J., Winter D.C.
ISSN
1365-2168 (Electronic)
ISSN-L
0007-1323
Statut éditorial
Publié
Date de publication
14/06/2022
Peer-reviewed
Oui
Volume
109
Numéro
7
Pages
632-636
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The molecular profile of early-onset colonic cancer is undefined. This study evaluated clinicopathological features and oncological outcomes of young patients with colonic cancer according to microsatellite status.
Anonymized data from an international collaboration were analysed. Criteria for inclusion were patients younger than 50 years diagnosed with stage I-III colonic cancer that was surgically resected. Clinicopathological features, microsatellite status, and disease-specific outcomes were evaluated.
A total of 650 patients fulfilled the criteria for inclusion. Microsatellite instability (MSI) was identified in 170 (26.2 per cent), whereas 480 had microsatellite-stable (MSS) tumours (relative risk of MSI 2.5 compared with older patients). MSI was associated with a family history of colorectal cancer and lesions in the proximal colon. The proportions with pathological node-positive disease (45.9 versus 45.6 per cent; P = 1.000) and tumour budding (20.3 versus 20.5 per cent; P = 1.000) were similar in the two groups. Patients with MSI tumours were more likely to have BRAF (22.5 versus 6.9 per cent; P < 0.001) and KRAS (40.0 versus 24.2 per cent; P = 0.006) mutations, and a hereditary cancer syndrome (30.0 versus 5.0 per cent; P < 0.001; relative risk 6). Five-year disease-free survival rates in the MSI group were 95.0, 92.0, and 80.0 per cent for patients with stage I, II, and III tumours, compared with 88.0, 88.0, and 65.0 per cent in the MSS group (P = 0.753, P = 0.487, and P = 0.105 respectively).
Patients with early-onset colonic cancer have a high risk of MSI and defined genetic conditions. Those with MSI tumours have more adverse pathology (budding, KRAS/BRAF mutations, and nodal metastases) than older patients with MSI cancers.
Anonymized data from an international collaboration were analysed. Criteria for inclusion were patients younger than 50 years diagnosed with stage I-III colonic cancer that was surgically resected. Clinicopathological features, microsatellite status, and disease-specific outcomes were evaluated.
A total of 650 patients fulfilled the criteria for inclusion. Microsatellite instability (MSI) was identified in 170 (26.2 per cent), whereas 480 had microsatellite-stable (MSS) tumours (relative risk of MSI 2.5 compared with older patients). MSI was associated with a family history of colorectal cancer and lesions in the proximal colon. The proportions with pathological node-positive disease (45.9 versus 45.6 per cent; P = 1.000) and tumour budding (20.3 versus 20.5 per cent; P = 1.000) were similar in the two groups. Patients with MSI tumours were more likely to have BRAF (22.5 versus 6.9 per cent; P < 0.001) and KRAS (40.0 versus 24.2 per cent; P = 0.006) mutations, and a hereditary cancer syndrome (30.0 versus 5.0 per cent; P < 0.001; relative risk 6). Five-year disease-free survival rates in the MSI group were 95.0, 92.0, and 80.0 per cent for patients with stage I, II, and III tumours, compared with 88.0, 88.0, and 65.0 per cent in the MSS group (P = 0.753, P = 0.487, and P = 0.105 respectively).
Patients with early-onset colonic cancer have a high risk of MSI and defined genetic conditions. Those with MSI tumours have more adverse pathology (budding, KRAS/BRAF mutations, and nodal metastases) than older patients with MSI cancers.
Mots-clé
Colonic Neoplasms/genetics, Colonic Neoplasms/surgery, Colorectal Neoplasms, Humans, Microsatellite Instability, Microsatellite Repeats/genetics, Mutation, Prognosis, Proto-Oncogene Proteins B-raf/genetics, Proto-Oncogene Proteins p21(ras)/genetics
Pubmed
Web of science
Création de la notice
26/09/2023 14:50
Dernière modification de la notice
15/02/2024 21:06
Données d'usage
